Background: A single dose of the potent class I histone deacetylase inhibitor (HDACi), vorinostat (VOR) upregulates HIV RNA expression within the resting CD4+ T cells of antiretroviral (ART)-treated, aviremic HIV+ patients. The ability of VOR to repeatedly disrupt latency is unproven, the optimal dosing schema is unknown, and the effect of repeated VOR exposure on host mechanisms that might contribute to viral expression is uncertain. Methodology: In a Phase I-II single-center study, HIV+ participants maintained suppressive ART, and resting CD4+ T cells were obtained for study via leukapheresis. Following a single VOR 400 mg dose, an increase in resting CD4+ T cell-associated HIV RNA (rc-RNA) was measured in all patients (Archin, Nature 2012), and consenting patients later received VOR 400 mg daily Monday-Wednesday for 4 weekly cycles, followed after a 4-8 week rest period by another 4 weekly cycles. VOR serum concentrations ([VOR]), measurements of histone acetylation within PBMCs, rc-RNA, total cellular HIV DNA, and quantitative viral outgrowth assays (QVOA) from resting CD4+ T cells were obtained. A population PK model was built from all available [VOR] data using nonlinear mixed effects modeling with NONMEM 7.2. The model was used to predict individual [VOR] at the time of leukapheresis and perform exploratory exposure-effect relationships. Results: In 5 patients VOR was well tolerated with no adverse events > Grade I; mild declines in platelet counts < Grade I were seen at late time points. Repeat dose [VOR] were similar to single dose. However, when measured by leukapheresis after dose 11 (2nd dose of cycle 4) and dose 22 (2nd dose of cycle 8) cellular histone acetylation was little increased from baseline, and measures of rc-RNA only modestly increased in some patients. QVOA and other assays were not significantly affected. [VOR] corresponding to the leukapheresis measurements show an exposure-effect relationship with clock-wise hysteresis, signifying tolerance to VOR over time. Conclusions: The results of this study suggests that HIV latency is disrupted by an initial VOR dose, but a refractory period of more than 24 hours ensues, which may reduce the responsiveness of the viral promoter to HDACi induction. Attempts to use HDACis to deplete persistent HIV infection will require a detailed understanding of the kinetic effects of HDACis on host cellular functions. Gene expression analysis to understand the complex cascade of events that follow VOR exposure in vivo are ongoing.